← SynDRA
FILIBUVIR
SynDRA canonical compound SYN0011926 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Mechanism of action | non-nucleoside reverse transcriptase inhibitor |
|---|
| Indication | hepatitis c |
|---|
| Disease area | infectious disease |
|---|
All known targets
Mechanisms of action (all sources)
- non-nucleoside reverse transcriptase inhibitor
- HCV NS5B INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- CYP1A2
- CYP2C19
- CYP2C8
- CYP2C9
- CYP2D6
- CYP3A4
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- PF-00868554
- PF-868554
- UNII-198J479Y2L
- 198J479Y2L
- (6R)-6-Cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl(1,2,4)triazolo(1,5-a)pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydro-2H-pyran-2-one
- (R)-6-Cyclopentyl-6-[2-(2,6-diethylpyridin-4-yl)ethyl]-3-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one
- Filibuvir [USAN:INN]
- 3frz
- PF 868554
- PF00868554
- filibuvirum
- RefChem:921608
- DTXCID501527731
- PF868554
- FILIBUVIR [INN]
- Filibuvir (USAN/INN)
- FILIBUVIR [USAN]
- FILIBUVIR [WHO-DD]
- orb1707311
- SCHEMBL1464441
- CHEBI:177773
- GLXC-07568
- MFCD15528932
- AKOS030532566
- EBC-501097
- NCGC00485400-01
- FC152905
- HY-10118
- MS-29356
- DB-322080
- CS-0002461
- NS00073286
- D09616
- G13864
- T15282
- فیلیبوویر
- BDBM50623375
- SCHEMBL12748294
- BDBM50623374
Look up FILIBUVIR in the interactive SynDRA portal →